Intradermal administration of DNA vaccine targeting Omicron SARS-CoV-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 08 2023
10 08 2023
Historique:
received:
08
03
2023
accepted:
06
08
2023
medline:
14
8
2023
pubmed:
11
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
Emerging SARS-CoV-2 Omicron variants are highly contagious with enhanced immune escape mechanisms against the initially approved COVID-19 vaccines. Therefore, we require stable alternative-platform vaccines that confer protection against newer variants of SARS-CoV-2. We designed an Omicron B.1.1.529 specific DNA vaccine using our DNA vaccine platform and evaluated the humoral and cellular immune responses. SD rats intradermally administered with Omicron-specific DNA vaccine via pyro-drive jet injector (PJI) thrice at 2-week intervals elicited high antibody titers against the Omicron subvariants as well as the ancestral strain. Indeed, the Omicron B.1.1.529-specific antibody titer and neutralizing antibody were higher than that of other strains. Longitudinal monitoring indicated that anti-spike (ancestral and Omicron) antibody titers decreased toward 30 weeks after the first vaccination dose. However, neutralization activity remained unaltered. Germinal center formation was histologically detected in lymph nodes in rats immunized with Omicron DNA vaccine. Ancestral spike-specific immune cell response was slightly weaker than Omicron spike-specific response in splenocytes with Omicron-adapted DNA vaccine, evaluated by ELISpot assay. Collectively, our findings suggest that Omicron targeting DNA vaccines via PJI can elicit robust durable antibody production mediated by germinal center reaction against this new variant as well as partially against the spike protein of other SARS-CoV-2 variants.
Identifiants
pubmed: 37563266
doi: 10.1038/s41598-023-40172-y
pii: 10.1038/s41598-023-40172-y
pmc: PMC10415318
doi:
Substances chimiques
Antibodies, Neutralizing
0
Vaccines, DNA
0
COVID-19 Vaccines
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13033Informations de copyright
© 2023. Springer Nature Limited.
Références
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Front Immunol. 2018 Oct 25;9:2469
pubmed: 30410492
AAPS PharmSciTech. 2019 Dec 9;21(1):19
pubmed: 31820256
Cell Res. 2022 Oct;32(10):949-952
pubmed: 35915244
Future Virol. 2021 Nov;:
pubmed: 34858516
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Nature. 2022 Apr;604(7904):141-145
pubmed: 35168246
Annu Rev Immunol. 1994;12:117-39
pubmed: 8011279
EClinicalMedicine. 2021 Aug;38:101020
pubmed: 34308319
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Semin Immunol. 2008 Feb;20(1):14-25
pubmed: 18261920
Cell Mol Immunol. 2022 Mar;19(3):447-448
pubmed: 35043006
Nat Rev Immunol. 2022 Jan;22(1):7-18
pubmed: 34873279
Sci Immunol. 2022 Apr 22;7(70):eabn8590
pubmed: 35113654
Pharmaceutics. 2022 Feb 17;14(2):
pubmed: 35214162
Sci Rep. 2022 Dec 3;12(1):20923
pubmed: 36463322
Cell. 2022 Mar 17;185(6):1041-1051.e6
pubmed: 35202566
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
NPJ Vaccines. 2021 Feb 22;6(1):28
pubmed: 33619260
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Vaccines (Basel). 2022 Aug 30;10(9):
pubmed: 36146505
Immunity. 2020 Dec 15;53(6):1281-1295.e5
pubmed: 33296685
Curr Top Microbiol Immunol. 2012;351:77-112
pubmed: 21472533
J Pharm Sci. 2019 Jul;108(7):2415-2420
pubmed: 30849461
Nat Commun. 2022 Jul 27;13(1):4350
pubmed: 35896523
Nat Commun. 2022 Jun 6;13(1):3250
pubmed: 35668119
Bull World Health Organ. 2011 Mar 1;89(3):221-6
pubmed: 21379418
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Vaccines (Basel). 2021 Sep 17;9(9):
pubmed: 34579270
Immunity. 2010 Oct 29;33(4):451-63
pubmed: 21029957
Curr Res Transl Med. 2022 Sep;70(4):103348
pubmed: 35489099
Nat Rev Microbiol. 2023 Feb;21(2):112-124
pubmed: 36307535
Nat Rev Immunol. 2015 Mar;15(3):137-48
pubmed: 25656706
Immunol Med. 2022 Dec;45(4):251-264
pubmed: 36001011
J Med Virol. 2022 May;94(5):1876-1885
pubmed: 35083761
Immunity. 2021 Aug 10;54(8):1841-1852.e4
pubmed: 34246326
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
Nat Med. 2022 Mar;28(3):490-495
pubmed: 35046573
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
N Engl J Med. 2022 Oct 6;387(14):1279-1291
pubmed: 36112399
Nat Biotechnol. 2021 Dec;39(12):1479-1482
pubmed: 34785814
Curr Opin Immunol. 2020 Aug;65:21-27
pubmed: 32259744
Nat Microbiol. 2022 Aug;7(8):1180-1188
pubmed: 35836002
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Cell. 2022 Feb 17;185(4):603-613.e15
pubmed: 35026152
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027